Research
Hormonal
High-efficacy anti-obesity medications (AOMs) like semaglutide and tirzepatide produce significant weight loss in the majority of patients, but a subset of non-responders exists, and predictors of response or intolerance are currently unknown.
High-efficacy AOMs like semaglutide and tirzepatide work for most people, but not all. If you are a non-responder, it is not your fault, and current science cannot yet predict who will respond. Discuss alternative strategies or phenotypes with your provider.
StrongQualifiesHIGH confidence
Indeed, more than 90% of patients on treatment at the 15 mg tirzepatide dose achieved weight loss of 10% or more. Similar findings were found in a randomized trial examining the GLP-1 receptor agonist semaglutide for weight loss in adolescents... However, they do not produce clinically significant weight loss in all people who take the drugs. This lack of response is unexplained.
Why this rating
Based on large RCTs and real-world data cited for tirzepatide and semaglutide.
Source
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Emily K. Woolf et al. · Obesity · 2025
DOI 10.1002/oby.70015
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genotype-based dietary interventions (low-carb vs. low-fat) do not significantly impact weight loss outcomes, suggesting that genotyping alone is not an effective precision medicine approach for weight loss.Good
- Phenotype-guided interventions (tailoring diet, medication, or exercise based on specific metabolic/behavioral traits like satiation or emotional eating) result in greater weight loss compared to non-phenotype-guided standard care.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →